Elite, SunGen Pharma Collaborate On Generics
By

By
Elite Pharmaceuticals, a Northvale, New Jersey-based company developing abuse-deterrent opioids and niche generic products, has formed a collaboration with SunGen Pharma, a North Brunswick, New Jersey-based company specializing in oral…

BI, Saniona Sign Schizophrenia Treatment Pact
By

By
Boehringer Ingelheim and Saniona, a biotechnology company based in Copenhagen, Denmark and focused on drugs for central nervous system diseases, autoimmune diseases, metabolic diseases, and pain therapies, have formed a…

TG Therapeutics Gets Orphan Drug Status For Anti-inflammatory Drug
By

By
TG Therapeutics, a New York-based clinical-stage biopharmaceutical company, has been granted orphan drug status by the US Food and Drug Administration (FDA) for ublituximab, an anti-inflammatory drug. Ublituximab is a…

Perrigo Gets Tentative FDA Approval For Generic Of Suprep
By

By
Perrigo Company has received tentative approval from the US Food and Drug Administration for the generic version of Braintree Laboratories' Suprep (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is…

Companion Medical Receives FDA OKA for Smart Insulin Delivery System
By

By
Companion Medical, a San Diego, California-based company focused on advanced technology to improve diabetes care, has been granted 510(k) clearance by the US Food and Drug Administration for the InPen…

Amgen Receives Complete Response Letter From FDA For Parsabiv
By

By
Amgen has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with…

IMS, Quintiles Names Leadership to Merged Company
By

By
IMS Health Holdings and Quintiles Transnational Holdings have announced key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of their merger, which is…

EMA Accepts Mylan, Biocon Application For Herceptin Biosimilar
By

By
The European Medicines Agency (EMA) has accepted a marketing authorization application filed by Mylan for a proposed biosimilar referencing Roche's Herceptin (trastuzumab), for certain HER2-positive breast and gastric cancers. Herceptin,…

Mylan To Launch Generic Version Of EpiPen Auto-Injector
By

By
Mylan expects to launch a generic version to EpiPen Auto-Injector (epinephrine injection, USP) in several weeks, pending completion of labeling revisions, the company said in a statement released on August…

Eisai Gets Approval In Japan For Anti-cancer Agent
By

By
Eisai has received approval in Japan for an additional indication of its anti-cancer agent, Treakisym (bendamustine hydrochloride) for injection 100 mg, in chronic lymphocytic leukemia. Treakisym is the subject of…